Open AccessVHH212 nanobody targeting the hypoxia-inducible factor 1α suppresses angiogenesis and potentiates gemcitabine therapy in pancreatic cancer <i>in vivo</i>
Author(s) -
Guangbo Kang,
Min Hu,
He Ren,
Jiewen Wang,
Xin Cheng,
Ruowei Li,
Bo Yuan,
Yasmine Balan,
Zixuan Bai,
He Huang
Publication year - 2021
Publication title -
cancer biology and medicine
Language(s) - English
Resource type - Journals
ISSN - 2095-3941
DOI - 10.20892/j.issn.2095-3941.2020.0568
Subject(s) - gemcitabine , pancreatic cancer , in vivo , cancer research , hypoxia inducible factors , vascular endothelial growth factor , angiogenesis , chemistry , tumor hypoxia , microbiology and biotechnology , antibody , biology , cancer , medicine , immunology , biochemistry , radiation therapy , genetics , vegf receptors , gene
We aimed to develop a novel anti-HIF-1α intrabody to decrease gemcitabine resistance in pancreatic cancer patients.